Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYEWITNESS: DTG/3TC in Virologically Suppressed HIV-1 Participants >= 50 Years Old
NCT05911360Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of dolutegravir, lamivudine in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Started Jul 2023; status: completed.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05911360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911360.